These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 23205461)
1. [109th Scientific Meeting of the Japanese Society of Internal Medicine: educational lecture: 13. TPO receptor agonist in the treatment of primary immune thrombocytopenia]. Tomiyama Y Nihon Naika Gakkai Zasshi; 2012 Sep; 101(9):2725-32. PubMed ID: 23205461 [No Abstract] [Full Text] [Related]
2. Reference guide for management of adult immune thrombocytopenia in Japan: 2019 Revision. Kashiwagi H; Kuwana M; Hato T; Takafuta T; Fujimura K; Kurata Y; Murata M; Tomiyama Y; Int J Hematol; 2020 Mar; 111(3):329-351. PubMed ID: 31897887 [No Abstract] [Full Text] [Related]
3. Thrombopoietin receptor agonists in patients with persistent or chronic immune thrombocytopenia. Agnelli Giacchello J; Valeri F; Boccadoro M; Borchiellini A Eur J Haematol; 2018 Mar; 100(3):304-307. PubMed ID: 29243329 [TBL] [Abstract][Full Text] [Related]
5. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study. Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388 [TBL] [Abstract][Full Text] [Related]
6. [Pathogenesis and management of immune thrombocytopenia]. Fujimura K Rinsho Ketsueki; 2014 Jan; 55(1):83-92. PubMed ID: 24492041 [No Abstract] [Full Text] [Related]
7. Is there any Role for Splenectomy in Adulthood Onset Chronic Immun e Thrombocytopenia in the Era of TPO Receptors Agonists? A Critic al Overview. Vibor M; Rogulj IM; Ostojic SK Cardiovasc Hematol Disord Drug Targets; 2017 Jul; 17(1):38-51. PubMed ID: 28034281 [TBL] [Abstract][Full Text] [Related]
8. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP). Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973 [TBL] [Abstract][Full Text] [Related]
9. The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study. Mahévas M; Fain O; Ebbo M; Roudot-Thoraval F; Limal N; Khellaf M; Schleinitz N; Bierling P; Languille L; Godeau B; Michel M Br J Haematol; 2014 Jun; 165(6):865-9. PubMed ID: 24725224 [TBL] [Abstract][Full Text] [Related]
10. [Progression of bone marrow fibrosis with reticulin and collagen hyperplasia during treatment with the thrombopoietin receptor agonist romiplostim in a patient with immune thrombocytopenia]. Kirito K; Komatsu N Rinsho Ketsueki; 2013 Mar; 54(3):295-9. PubMed ID: 23676646 [TBL] [Abstract][Full Text] [Related]
11. What is the role of novel thrombopoietic agents in the management of acute leukemia? Kuter DJ Best Pract Res Clin Haematol; 2016 Dec; 29(4):372-378. PubMed ID: 27890262 [TBL] [Abstract][Full Text] [Related]
12. Beyond immune thrombocytopenia: the evolving role of thrombopoietin receptor agonists. Rodeghiero F; Carli G Ann Hematol; 2017 Sep; 96(9):1421-1434. PubMed ID: 28275823 [TBL] [Abstract][Full Text] [Related]
13. Guest editorial: Pathophysiology and management of thrombocytopenia: possible clinical application of TPO receptor agonists. Tomiyama Y Int J Hematol; 2013 Jul; 98(1):8-9. PubMed ID: 23793996 [No Abstract] [Full Text] [Related]
14. Usage of eltrombopag for chronic immune thrombocytopenia as a pretreatment for splenectomy. Uwagawa T; Misawa T; Furukawa K; Ito R; Futagawa Y; Yahagi Y; Aiba K; Yanaga K Acta Haematol; 2013; 129(1):45-7. PubMed ID: 23128016 [No Abstract] [Full Text] [Related]
15. Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults. Červinek L; Mayer J; Doubek M Int J Hematol; 2015 Jul; 102(1):7-11. PubMed ID: 25833724 [TBL] [Abstract][Full Text] [Related]
16. Exposure to non-corticosteroid treatments in adult primary immune thrombocytopenia before the chronic phase in the era of thrombopoietin receptor agonists in France. A nationwide population-based study. Moulis G; Lapeyre-Mestre M; Montastruc JL; Sailler L Autoimmun Rev; 2015 Feb; 14(2):168-73. PubMed ID: 25461471 [TBL] [Abstract][Full Text] [Related]
17. Potential therapeutics for antiphospholipid antibody associated thrombocytopenia: A systematic review and meta-analysis. Abe N; Oku K; Amengual O; Fujieda Y; Kato M; Bohgaki T; Yasuda S; Mori R; Morishita E; Suzuki-Inoue K; Atsumi T Mod Rheumatol; 2020 Jan; 30(1):116-124. PubMed ID: 30557100 [No Abstract] [Full Text] [Related]
18. Eltrombopag: an update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia. Kühne T; Imbach P Ann Hematol; 2010 Jul; 89 Suppl 1():67-74. PubMed ID: 20405290 [TBL] [Abstract][Full Text] [Related]
19. Thrombopoietin levels in patients with disorders of platelet production: diagnostic potential and utility in predicting response to TPO receptor agonists. Makar RS; Zhukov OS; Sahud MA; Kuter DJ Am J Hematol; 2013 Dec; 88(12):1041-4. PubMed ID: 23913253 [TBL] [Abstract][Full Text] [Related]
20. Autoantibodies to thrombopoietin and the thrombopoietin receptor in patients with immune thrombocytopenia. Nazy I; Kelton JG; Moore JC; Clare R; Horsewood P; Smith JW; Ivetic N; D'Souza V; Li N; Arnold DM Br J Haematol; 2018 Apr; 181(2):234-241. PubMed ID: 29532903 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]